Blood Screening Market

Blood Screening Market - Global Market Share, Trends, Analysis and Forecasts, 2023 - 2032
Frequently asked questions about this report

Growing awareness regarding blood donation, increasing requirement of healthy blood form clinical applications, prevalence of infectious diseases, rising number of surgical procedures, and stringent regulations to monitor blood quality are the primary forces shaping the global blood screening market.

North America contributed the largest share to the global blood screening market in 2019 and is expected to witness prominent growth during the forecast period. Prevalence of infectious diseases, rising demand for healthy blood, and growth in volume of donated blood are the key factors contributing towards the growth of North America blood screening market.

Based on technology, the blood screening market is segmented into nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), enzyme immunoassay (EIA), next-generation sequencing (NGS), western blotting, and others.

The major active players are Abbott Laboratories, Beckman Coulter (Danaher Corporation), Becton Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Grifols, S.A., Ortho Clinical Diagnostics, Siemens, and Thermo Fisher Scientific.

The blood screening market is estimated to expand at a CAGR of 7.7% from 2023 to 2032.

The blood screening market was valued at US$ 2.3 billion in 2021.